Dr. Reddy’s Lab will soon introduce 4 new medicines for these diseases including skin cancer.
Dr. Reddy’s Jab has earned Rs 795 crore during the financial year ended 31 March 2020. Due to this, the company had an income of Rs 475 crore during the last financial year, i.e. in the financial year 2019-20, the company’s earnings have registered a growth of 67 percent.
Hyderabad. The country’s pharmaceutical company Dr. Reddy’s Laboratories has reached the final stage of introducing 4 new drugs, including cancer treatment. At the same time, some drugs are still in the initial stage. The company said that these new products are related to Pediatrics, Dermatology and Oncology.
The company is making medicines to treat these diseases
Dr. Reddy’s said that DFD-11 (Xeglyze) included in the new products is being made for the treatment of head lice in children aged 6 months or more. At the same time, PPC-06 (Tepilamide Fumarate) will be offered for the treatment of plaque psoriasis at the age of 18 years or more. In addition, Compound E7777 will be effective in the treatment of skin-related T-cell lymphoma.